Weekly Respiratory Research Analysis
This week’s respiratory literature highlights three broad priorities: scalable implementation to reduce antibiotic overuse, host-directed metabolic targets to modulate pneumonia inflammation, and clade-resolved vaccine effects on bacterial colonization that inform adult vaccination strategy. High-quality randomized and translational studies (cluster RCT, mechanistic in vivo work, and a randomized human challenge) offer near-term policy and clinical implications across prevention, therapeutics, a
Summary
This week’s respiratory literature highlights three broad priorities: scalable implementation to reduce antibiotic overuse, host-directed metabolic targets to modulate pneumonia inflammation, and clade-resolved vaccine effects on bacterial colonization that inform adult vaccination strategy. High-quality randomized and translational studies (cluster RCT, mechanistic in vivo work, and a randomized human challenge) offer near-term policy and clinical implications across prevention, therapeutics, and stewardship.
Selected Articles
1. Effects of a comprehensive antibiotic stewardship program on antibiotic prescribing for acute respiratory infections in rural facilities: a cluster randomized trial.
A pragmatic cluster randomized trial in 34 township hospitals (97,239 ARI consultations) showed a digitally enabled, multifaceted stewardship package (EMR‑embedded prompts, clinician training, monthly peer-review feedback, and patient app education) reduced antibiotic prescribing for acute respiratory infections from 71% to 26% (adjusted risk difference −39 percentage points) without increasing 30‑day respiratory or sepsis hospitalizations.
Impact: Provides large-scale, randomized evidence that digital, team-based stewardship can dramatically reduce inappropriate antibiotic use for respiratory infections without compromising short-term safety — high policy relevance for AMR control.
Clinical Implications: Health systems and primary care programs should adopt integrated EMR prompts, clinician audit-feedback, and patient education to reduce antibiotic overprescribing for ARIs; policymakers can consider scaling such packages as part of AMR strategies.
Key Findings
- Antibiotic prescribing for ARIs fell from 71% (control) to 26% (intervention), adjusted risk difference −39 percentage points (95% CI −47 to −29; P<0.001).
- No increase in 30-day hospitalizations for respiratory illness or sepsis was observed (adjusted risk difference 0.2 percentage points).
- Intervention combined EMR-embedded concise guidelines/prompts, clinician training, monthly peer prescribing reviews, and patient education via smartphone app.
2. Phosphoglycerate dehydrogenase-mediated serine reprogramming aggravates macrophage hyperinflammation in murine Pseudomonas aeruginosa pneumonia.
Mechanistic preclinical study shows PHGDH-driven L‑serine synthesis reprograms macrophage one‑carbon metabolism to strengthen H3K27me3–DUSP4 interactions and ERK1/2 phosphorylation, amplifying inflammation in Pseudomonas aeruginosa pneumonia. Genetic myeloid-specific PHGDH deletion, pharmacologic PHGDH inhibition, and dietary L‑serine restriction each reduced lung injury, bacterial burden, and improved survival in mice.
Impact: Identifies a druggable host metabolic–epigenetic axis (PHGDH/serine → one‑carbon → epigenetic modulation) that meaningfully altered outcomes in vivo, supporting development of host-directed adjunctive therapies for severe bacterial pneumonia.
Clinical Implications: PHGDH inhibitors or dietary modulation of serine pathways may be developed as adjunctive host-directed treatments to attenuate injurious inflammation in Pseudomonas and potentially other severe pneumonias; translational studies in human macrophages and early-phase trials are warranted.
Key Findings
- PHGDH inhibition (genetic and pharmacologic) suppressed macrophage hyperactivation and pro‑inflammatory cytokine production.
- Myeloid‑specific PHGDH deletion, pharmacologic inhibition, and dietary L‑serine restriction each reduced lung injury and bacterial burden and improved survival in murine P. aeruginosa pneumonia.
- Mechanism: PHGDH-driven L‑serine synthesis augments one‑carbon metabolism, enhancing H3K27me3–DUSP4 interaction and ERK1/2 phosphorylation to amplify inflammation.
3. The effect of pneumococcal conjugate vaccine and pneumococcal polysaccharide vaccine on nasopharyngeal colonisation following human infection challenge with serotype 3 and serotype 6B (PREVENTING PNEUMO 2): a double-masked, randomised, controlled, phase 4 trial.
A randomized, double-masked human challenge study (Spn3 n=407; Spn6B subgroup n=243) found PCV13 provided significant protection against serotype 3 clade II colonization (RR 0.71) but not clade Iα, and provided 60% reduction in serotype 6B colonization at 6 months. PPV23 did not prevent clade Iα colonization. No severe adverse events were observed.
Impact: Provides randomized, clade‑resolved human evidence on vaccine effects on colonization — a transmission-relevant endpoint — clarifying why serotype 3 disease persists and informing adult vaccination policy and next-generation vaccine design.
Clinical Implications: Supports direct adult PCV13 use in settings where serotype 3 disease persists, with attention to clade heterogeneity; indicates PPV23 may not prevent colonization by certain serotype 3 clades and that vaccine design should account for clade differences.
Key Findings
- PCV13 reduced Spn3 colonization overall by 16% (RR 0.84; p=0.068) and significantly reduced clade II acquisition (RR 0.71; p=0.009) but did not protect against clade Iα (RR 1.01).
- PCV13 reduced Spn6B colonization by 60% at 6 months (RR 0.40; p=0.002).
- PPV23 did not prevent Spn3 clade Iα colonization; no severe adverse events were observed in the challenge protocol.